Q4 2019 Redhill Biopharma Ltd Earnings Call Transcript
Good day, and welcome to the RedHill Biopharma's Full Year 2019 Financial Results Conference Call. At this time, I would like to introduce to the conference call RedHill's CEO, Mr. Dror Ben-Asher; Micha Ben-Chorin, RedHill's CFO; Mr. Rick Scruggs, RedHill's Chief Commercial Officer; Mr. Gilead Raday, RedHill's Chief Operating Officer; and Mr. Guy Goldberg, RedHill's Chief Business Officer. Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.
This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to RedHill's expectations regarding the timing of the commercial launch of Talicia; the closing of the acquisition of rights to Movantik and the funding of the nondilutive financing agreement with Healthcare Royalty Partners; the business promotion and other efforts related to RedHill's commercialization activities and the initiation, timing, progress and results of RedHill's research,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |